Onychomycosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers Onychomycosis Treatment Market Trends and it is segmented by Treatment Type (Drugs, Laser Therapy, and Photodynamic Therapy), Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The market provides the value (in USD million) for the above segments.

Onychomycosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Onychomycosis Treatment Industry Overview

The onychomycosis treatment market is fragmented and competitive and consists of several major players. Companies are focusing on developments, collaborations, and product launches to strengthen their market position. For instance, in April 2020, the US Food and Drug Administration expanded the approval of Jublia manufactured by Bausch Health. Jublia is a topical solution used to treat onychomycosis in the toenail(s) in patients aged six years and above.

Some of the players currently dominating the market are Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), Galderma SA, Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson, Bayer AG, Dr. Reddy's Laboratories Ltd, Cipla Ltd, Medimetriks Pharmaceuticals Inc., and Lumenis Ltd.

Onychomycosis Treatment Market Leaders

  1. Bausch Health Companies Inc (Valeant Pharmaceuticals Inc)

  2. Galderma S.A.

  3. Novartis AG

  4. Pfizer, Inc

  5. Moberg Pharma AB

  6. *Disclaimer: Major Players sorted in no particular order
Onychomycosis Treatment Market Concentration

Onychomycosis Treatment Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?